CN
CNMD.US CONMED Corporation
- Market cap
- USD 1.51B
- P/E
- 21.0x
- P/B
- 1.42x
- ROE
- 7.1%
- Dividend yield
- 1.64%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CNMD.US undervalued?
Graham numberCNMD.US trades 15.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CONMED Corporation fundamental analysis
No fundamental analysis for CONMED Corporation yet.
CONMED Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, flui…
Full company profileCONMED Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CONMED Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 764M | 796M | 860M | 955M | 862M | 1.01B | 1.05B | 1.24B | 1.31B | 1.37B | 1.33B |
| Gross Profit | 408M | 431M | 469M | 525M | 460M | 568M | 571M | 676M | 733M | 725M | 760M |
| Operating Income | 37.7M | 46.9M | 71.3M | 79.1M | 46.0M | 110M | 70.1M | 121M | 200M | 141M | 132M |
| EBITDA | 90.0M | 105M | 133M | 146M | 118M | 179M | 27.6M | 172M | 252M | 176M | 208M |
| Net Income | 14.7M | 55.5M | 40.9M | 28.6M | 9.52M | 62.5M | -80.6M | 64.5M | 132M | 47.1M | 75.6M |
| EPS | 0.52 | 1.97 | 1.41 | 0.97 | 0.32 | 1.94 | -2.68 | 2.04 | 4.26 | 1.51 | 2.51 |
| Balance Sheet | |||||||||||
| Total Assets | 1.33B | 1.36B | 1.37B | 1.78B | 1.75B | 1.77B | 2.30B | 2.30B | 2.31B | 2.33B | 2.30B |
| Total Liabilities | 748M | 727M | 707M | 1.06B | 1.04B | 981M | 1.55B | 1.47B | 1.34B | 1.29B | 1.24B |
| Shareholders' Equity | 581M | 631M | 662M | 710M | 709M | 785M | 746M | 834M | 963M | 1.03B | 1.06B |
| Cash & Short-term Investments | 27.4M | 32.6M | 17.5M | 25.9M | 27.4M | 20.8M | 28.9M | 24.3M | 24.5M | 40.8M | 48.0M |
| Total Debt | 498M | 486M | 457M | 793M | 776M | 685M | 1.05B | 991M | 906M | 835M | 816M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 38.2M | 65.6M | 74.7M | 95.1M | 64.5M | 112M | 33.4M | 125M | 167M | 171M | 133M |
| Capital Expenditure | 14.8M | 12.8M | 16.5M | 20.1M | 13.0M | 14.9M | 21.8M | 19.0M | 13.1M | 19.8M | 11.3M |
| Free Cash Flow | 23.5M | 52.7M | 58.2M | 75.1M | 51.5M | 96.9M | 11.6M | 106M | 154M | 151M | 122M |
| Ratios | |||||||||||
| ROE | 2.5% | 8.8% | 6.2% | 4.0% | 1.3% | 8.0% | -10.8% | 7.7% | 13.8% | 4.6% | 7.1% |
| ROA | 1.1% | 4.1% | 3.0% | 1.6% | 0.5% | 3.5% | -3.5% | 2.8% | 5.7% | 2.0% | 3.3% |
| Net Profit Margin | 1.9% | 7.0% | 4.8% | 3.0% | 1.1% | 6.2% | -7.7% | 5.2% | 10.1% | 3.4% | 5.7% |
| Debt to Equity | 0.86x | 0.77x | 0.69x | 1.12x | 1.10x | 0.87x | 1.41x | 1.19x | 0.94x | 0.81x | 0.77x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CONMED Corporation dividends
- Dividend yield
- 1.64%
- Forward dividend
- -
- Payout ratio
- 52.6%
- Ex-dividend date
- Sep 15, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 24.7M | 0.79 | 52.6% |
| 2024 | USD 24.7M | 0.79 | 18.6% |
| 2023 | USD 24.5M | 0.78 | 38.0% |
| 2022 | USD 24.0M | 0.80 | - |
| 2021 | USD 23.3M | 0.72 | 37.2% |
| 2020 | USD 22.8M | 0.77 | 239.8% |
| 2019 | USD 22.6M | 0.77 | 79.0% |
| 2018 | USD 22.4M | 0.78 | 54.9% |
| 2017 | USD 22.3M | 0.79 | 40.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Sep 10, 2001.
Who owns CONMED Corporation
- Insiders 0.44%
- Institutions 99.56%
- Public & others 0.00%
- Shares outstanding 29.8M
- Free float 29.5M
Top funds holding CNMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1.80M | 6.04% | -0.24% | Oct 2026 |
| Undiscovered Managers Behavioral Val L | 1.20M | 4.04% | -4.98% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 958K | 3.21% | 0.00% | Sep 2026 |
| American Funds SMALLCAP World A | 801K | 2.69% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 778K | 2.61% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 674K | 2.26% | -2.53% | Sep 2026 |
| DFA U.S. Small Cap Value I | 557K | 1.87% | +42.97% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 439K | 1.47% | -0.24% | Sep 2026 |
| Harbor Small Cap Value Instl | 382K | 1.28% | -1.90% | Sep 2026 |
| Fidelity Small Cap Index | 338K | 1.13% | +0.16% | Aug 2026 |
| Invenomic Institutional | 299K | 1.00% | -19.89% | Jul 2026 |
| iShares Russell 2000 Value ETF | 290K | 0.97% | 0.00% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 272K | 0.91% | -0.05% | Oct 2026 |
| Glenmede Small Cap Equity Adv | 264K | 0.89% | -9.99% | Sep 2026 |
| iShares S&P Small-Cap 600 Value ETF | 248K | 0.83% | 0.00% | Oct 2026 |
| Vanguard Strategic Equity Inv | 239K | 0.80% | +12.96% | Sep 2026 |
| Vanguard Tax-Managed Small Cap Adm | 230K | 0.77% | 0.00% | Sep 2026 |
| Schwab Fundamental U.S. Small CompanyETF | 180K | 0.60% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 179K | 0.60% | +1.00% | Sep 2026 |
| Columbia Small Cap Value Discv A | 169K | 0.57% | +0.72% | Sep 2026 |
Top institutions holding CNMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 4.82M | 16.18% | -0.09% | Jun 2026 |
| Earnest Partners LLC | 2.51M | 8.41% | -2.50% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.19M | 7.34% | +5.41% | Jun 2026 |
| Fuller & Thaler Asset Management Inc | 1.58M | 5.30% | -3.77% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.47M | 4.95% | +11.89% | Sep 2026 |
| State Street Corp | 1.42M | 4.76% | +2.42% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.36M | 4.55% | -2.05% | Jun 2026 |
| Bank of America Corp | 1.34M | 4.50% | -4.36% | Jun 2026 |
| SEI Investments Co | 988K | 3.32% | -1.65% | Jun 2026 |
| Invenomic Capital Management, LP | 842K | 2.83% | -9.89% | Jun 2026 |
| Capital Research Global Investors | 824K | 2.76% | -11.00% | Jun 2026 |
| Geode Capital Management, LLC | 790K | 2.65% | +6.40% | Jun 2026 |
| Two Sigma Investments LLC | 729K | 2.45% | -6.84% | Jun 2026 |
| Allspring Global Investments Holdings, LLC | 618K | 2.08% | +6.13% | Jun 2026 |
| Cooke & Bieler LP | 573K | 1.92% | -41.94% | Jun 2026 |
| Paradigm Capital Management, Inc. | 538K | 1.81% | 0.00% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 477K | 1.60% | +13.79% | Jun 2026 |
| Charles Schwab Investment Management Inc | 471K | 1.58% | -1.58% | Jun 2026 |
| Silvercrest Asset Management Group LLC | 441K | 1.48% | -31.95% | Jun 2026 |
| The Goldman Sachs Group Inc | 437K | 1.47% | -8.35% | Jun 2026 |
CONMED Corporation company profile
- Company name
- CONMED Corporation
- Ticker
- CNMD.US
- Exchange
- USA Stocks
- Listed since
- Jul 23, 1987
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3,900
- Fiscal year end
- December
- Address
- 11311 Concept Boulevard, Largo, FL, United States, 33773
- Phone
- 727 392 6464
- Website
- conmed.com
About CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solutions comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures; and products to treat diseases of dilation, hemostasis, biliary, stricture management, and infection prevention, as well as ECG electrodes, EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
CONMED Corporation management
10- Mr. Patrick J. BeyerPresident, CEO & Director · born 1966
- Ms. Hollie K. FoustExecutive VP, General Counsel & Corporate Secretary · born 1975
- Mr. Peter K. ShagoryExecutive Vice President of Strategy & Corporate Development · born 1969
- Mr. Brent LalomiaExecutive VP of Regulatory Affairs, Quality Assurance, Clinical Affairs, Commercial Operations & IT · born 1975
- Mr. John E. Gallagher IIIExecutive VP, CFO and Principal Financial & Accounting Officer · born 1973
- Mr. Josep Lluis LlorensExecutive VP Global Supply Chain Management & Operations · born 1963
- Mr. Richard GlazeChief Information Officer · born 1966
- Keith SeatonVice President of Compliance
- Mr. John David FerrellExecutive Vice President of Human Resources · born 1968
- Mr. Curt R. HartmanSpecial Advisor · born 1964